Will the SOLIDARITY mega clinical trial from WHO find a treatment for COVID-19?
Market Rules
As the COVID-19 pandemic continues to spread around the world, scientists and pharmaceutical companies are rushing to find a treatment that could stop the virus and save critically ill patients.
In order to speed things up, the World Health Organization (WHO) launched on March 20th, 2020, a large global trial, called SOLIDARITY. The study, which could include many thousands of patients in dozens of countries, has been designed to be as simple as possible so that even hospitals overwhelmed by an onslaught of Covid-19 patients could participate.
WHO is focusing on what it says are the four most promising therapies:
- an experimental antiviral compound called remdesivir;
- the malaria medications chloroquine and hydroxychloroquine;
- a combination of two HIV drugs, lopinavir and ritonavir;
- and that same combination of lopinavir and ritonavir plus interferon-beta, an immune system messenger that can help cripple viruses.
If by December 31st, 2021, the WHO announces that at least one of the four treatment approaches evaluated in the SOLIDARITY clinical trial was confirmed to be an effective treatment against COVID-19, this question will be resolved as "Yes".